Skip to main content

The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)


Management of regional lymph nodes in patients with melanoma has evolved significantly in recent years. The value of nodal intervention, long utilized for its perceived therapeutic benefit, has now shifted to that of a critical prognostic procedure used to guide clinical decision making. This review focuses on the three landmark, randomized controlled trials evaluating the role of surgery for regional lymph nodes in melanoma: Multicenter Selective Lymphadenectomy Trial I (MSLT-I), German Dermatologic Cooperative Oncology Group-Selective Lymphadenectomy Trial (DeCOG-SLT), and Multicenter Selective Lymphadenectomy Trial II (MSLT-II).

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. New Engl J Med. 2006;355(13):1307–1317.

    CAS  Article  Google Scholar 

  2. 2.

    Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. New Engl J Med. 2014;370(7):599–609.

    CAS  Article  Google Scholar 

  3. 3.

    Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–767.

    Article  Google Scholar 

  4. 4.

    Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2222.

    Article  Google Scholar 

  5. 5.

    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.

    CAS  Article  Google Scholar 

  6. 6.

    Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823.

    CAS  Article  Google Scholar 

  7. 7.

    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835.

    CAS  Article  Google Scholar 

  8. 8.

    Snow HM. Melanotic cancerous disease. Lancet. 1982;140:869–922.

    Google Scholar 

  9. 9.

    Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7(2):87–97.

    CAS  Article  Google Scholar 

  10. 10.

    Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793–796.

    CAS  PubMed  Google Scholar 

  11. 11.

    Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49(11):2420–2430.

    CAS  Article  Google Scholar 

  12. 12.

    Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61(9):697–705.

    CAS  Article  Google Scholar 

  13. 13.

    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–399.

    CAS  Article  Google Scholar 

  14. 14.

    Altstein LL, Li G, Elashoff RM. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Stat Med. 2011;30(7):709–717.

    Article  Google Scholar 

  15. 15.

    Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17(12):3324–3329.

    Article  Google Scholar 

  16. 16.

    Nelson DW, Stern S, Elashoff DE, et al. Impact of time between diagnosis and SLNB on outcomes in cutaneous melanoma. J Am Coll Surg. 2017;225(2):302–311.

    Article  Google Scholar 

  17. 17.

    Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–2555.

    Article  Google Scholar 

  18. 18.

    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.

  19. 19.

    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206.

    Article  Google Scholar 

  20. 20.

    Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(4):367–402.

    Article  Google Scholar 

  21. 21.

    Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018;25(2):356–377.

    Article  Google Scholar 

  22. 22.

    Leung AM, Morton DL, Ozao-Choy J, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg. 2013;148(9):879–884.

    Article  Google Scholar 

  23. 23.

    Ariyan C, Brady MS, Gonen M, Busam K, Coit D. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(1):186–190.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Danielle M. Bello MD.

Ethics declarations


Dr. Bello has worked as a consultant for survivornet. Dr. Faries serves on advisory boards for Novartis, Pulse Bioscience, and Bristol-Myers Squibb. He is a consultant for Delcath Systems.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bello, D.M., Faries, M.B. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol 27, 15–21 (2020).

Download citation